Rami Akel, MD
Interventional Cardiology · Hudson, FLNPI 1144362245
Payments from drug & device makers
Across 595 payments — averaging $161.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$32K
- Cardiovascular Systems Inc.$17K
- Inari Medical, Inc.$17K
- Penumbra, Inc.$10K
- Edwards Lifesciences$5K
- Boston Scientific$4K
- plus $11K from 28 others
What the payments were for
- Consulting fees$14,79015%
- Speaking & faculty fees$43,39345%
- Travel & lodging$15,09316%
- Food & beverage$22,44723%
- Education$1030%
- Gifts$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 152 | $31,611 |
| Cardiovascular Systems Inc. | 97 | $17,327 |
| Inari Medical, Inc. | 32 | $16,888 |
| Penumbra, Inc. | 27 | $10,412 |
| Edwards Lifesciences | 24 | $5,411 |
| Boston Scientific | 46 | $3,651 |
| Abbott | 58 | $3,445 |
| Abiomed | 34 | $1,564 |
| Shockwave Medical, Inc | 35 | $992 |
| Angiodynamics, Inc. | 17 | $945 |
| W. L. Gore & Associates, Inc. | 5 | $902 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $332 |
| Cook Medical LLC | 6 | $316 |
| AstraZeneca | 5 | $222 |
| Janssen Scientific Affairs, LLC | 2 | $210 |
| Novartis | 11 | $172 |
| Inspiremd Ltd | 2 | $164 |
| E.r. Squibb & Sons, L.L.C. | 7 | $164 |
| Cardiva Medical, Inc. | 3 | $162 |
| Corindus Inc. | 2 | $159 |
| Johnson & Johnson | 2 | $144 |
| Boehringer Ingelheim | 6 | $123 |
| EKOS Corporation | 1 | $97 |
| Actelion Pharmaceuticals US, Inc. | 1 | $89 |
| Atricure, Inc. | 1 | $89 |
| Pfizer | 3 | $68 |
| Cordis US CORP. | 1 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $43 |
| Irhythm Technologies, Inc. | 2 | $38 |
| Siemens Medical Solutions USA, Inc. | 1 | $30 |
| Endologix LLC | 1 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$22,165
- CT THROMBECTOMY SYSTEM KIT$18,894
- Indigo System$9,897
- Peripheral Orbital Atherectomy System$8,145
- Coronary Orbital Atherectomy System$7,796
- FlowTriever$5,953
- ClotTriever$5,953
- Edwards SAPIEN 3 Transcatheter Heart Valve$4,131
- COREVALVE EVOLUT R$3,677
- FLOWTRIEVER CATHETER, S$2,101
- TRICLIP$1,239
- ROTABLATOR$1,227
- Achieve$914
- Impella$505
- NAVITOR$482
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$464
- AlphaVac$436
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$427
- Valiant Navion$423
- SAPIEN 3 Ultra RESILIA$420
How this compares
$95,938 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 467 | $510,817 |
| EntrestoSacubitril/Valsartan | 105 | $123,910 |
| XareltoRivaroxaban | 64 | $80,021 |
| MultaqDronedarone Hcl | 18 | $22,621 |
| Dofetilide | 77 | $19,534 |
| BrilintaTicagrelor | 12 | $13,249 |
| FarxigaDapagliflozin Propanediol | 14 | $11,099 |
| Metoprolol Succinate | 554 | $8,381 |
| Praluent PenAlirocumab | 17 | $8,175 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 26 | $6,751 |
| ClopidogrelClopidogrel Bisulfate | 402 | $4,940 |
| Losartan Potassium | 302 | $2,900 |
| Rosuvastatin Calcium | 223 | $2,745 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 204 | $2,634 |
| Midodrine Hcl | 20 | $2,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $510,817467 claims |
| NovartisEntresto | $172 | $123,910105 claims |
| Johnson & JohnsonXarelto | $144 | $80,02164 claims |
| AstraZenecaBrilinta, Farxiga | $222 | $24,34826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Hudson
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.